Today it was reported that the VP Finance and Chief Accounting Officer of EyePoint Pharmaceuticals Inc (EYPT), Leonard Ross, exercised options to buy 5,000 EYPT shares at $1.81 a share, for a total transaction value of $9,050.
This recent transaction increases Leonard Ross’ holding in the company by 6.72% to a total of $139.8K. In addition to Leonard Ross, 3 other EYPT executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on EyePoint Pharmaceuticals Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $2.44 million and GAAP net loss of $11.59 million. In comparison, last year the company earned revenue of $928K and had a GAAP net loss of $6.98 million. Currently, EyePoint Pharmaceuticals Inc has an average volume of 886.4K.
Starting in April 2018, EYPT received 23 Buy ratings in a row.
The insider sentiment on EyePoint Pharmaceuticals Inc has been positive according to 23 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
